SLC5A2 and atherosclerosis: ADA’s advice regarding preferential use of Sodium-glucose co-transporter2 (SGLT2) inhibitors or Glucagon-like peptide-1 receptor agonists (GLP1RA) in patients with known or suspected atherosclerotic cardiovascular disease (ASCVD) was first given in 2018 and was not applicable to this cohort.